{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T01:35:41Z","timestamp":1789263341194,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00403-018-1881-1","type":"journal-article","created":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T15:43:28Z","timestamp":1543679008000},"page":"63-69","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better?"],"prefix":"10.1007","volume":"311","author":[{"given":"Kamran","family":"Balighi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Daneshpazhooh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HamidReza","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrnoosh","family":"Badakhsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Teimourpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Houshang","family":"Ehsani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arghavan","family":"Azizpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Akbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Mahdavinia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojtaba","family":"Ghasemiadl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6765-8830","authenticated-orcid":false,"given":"Soheil","family":"Tavakolpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,1]]},"reference":[{"key":"1881_CR1","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/archdermatol.2009.9","volume":"145","author":"C Abasq","year":"2009","unstructured":"Abasq C, Mouquet H, Gilbert D, Tron F, Grassi V, Musette P, Joly P (2009) ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus. Arch Dermatol 145:529\u2013535. \n                    https:\/\/doi.org\/10.1001\/archdermatol.2009.9","journal-title":"Arch Dermatol"},{"key":"1881_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.intimp.2016.02.013","volume":"34","author":"AR Ahmed","year":"2016","unstructured":"Ahmed AR, Nguyen T, Kaveri S, Spigelman ZS (2016) First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up. Int Immunopharmacol 34:25\u201331. \n                    https:\/\/doi.org\/10.1016\/j.intimp.2016.02.013","journal-title":"Int Immunopharmacol"},{"key":"1881_CR3","doi-asserted-by":"publisher","first-page":"WC01","DOI":"10.7860\/JCDR\/2017\/21868.9717","volume":"11","author":"V Anandan","year":"2017","unstructured":"Anandan V, Jameela WA, Sowmiya R, Kumar MMS, Lavanya P (2017) Rituximab: a magic bullet for pemphigus. J Clin Diagn Res 11:WC01\u2013WC06. \n                    https:\/\/doi.org\/10.7860\/JCDR\/2017\/21868.9717","journal-title":"J Clin Diagn Res"},{"key":"1881_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12671","author":"K Balighi","year":"2018","unstructured":"Balighi K, Sakhi RS, Daneshpazhooh M, Mahmoudi H, Teimourpour A, Tavakolpour S (2018) Anti-desmoglein-1 levels as predictor of prednisolone tapering in pemphigus vulgaris patients treated with rituximab. Dermatol Ther. \n                    https:\/\/doi.org\/10.1111\/dth.12671","journal-title":"Dermatol Ther"},{"key":"1881_CR5","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1001\/archderm.143.8.1033","volume":"143","author":"G Cianchini","year":"2007","unstructured":"Cianchini G, Corona R, Frezzolini A, Ruffelli M, Didona B, Puddu P (2007) Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. Arch Dermatol 143:1033\u20131038. \n                    https:\/\/doi.org\/10.1001\/archderm.143.8.1033","journal-title":"Arch Dermatol"},{"key":"1881_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00281-015-0541-1","volume":"38","author":"G Zenzo Di","year":"2016","unstructured":"Di Zenzo G, Amber KT, Sayar BS, Muller EJ, Borradori L (2016) Immune response in pemphigus and beyond: progresses and emerging concepts. Semin Immunopathol 38:57\u201374. \n                    https:\/\/doi.org\/10.1007\/s00281-015-0541-1","journal-title":"Semin Immunopathol"},{"key":"1881_CR7","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1111\/bjd.13823","volume":"173","author":"RJ Feldman","year":"2015","unstructured":"Feldman RJ (2015) Paradoxical worsening of pemphigus vulgaris following rituximab therapy. Br J Dermatol 173:858\u2013859. \n                    https:\/\/doi.org\/10.1111\/bjd.13823","journal-title":"Br J Dermatol"},{"key":"1881_CR8","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1001\/jamadermatol.2014.2421","volume":"151","author":"S Ingen-Housz-Oro","year":"2015","unstructured":"Ingen-Housz-Oro S, Valeyrie-Allanore L, Cosnes A, Ortonne N, Hue S, Paul M, Wolkenstein P, Chosidow O (2015) First-line treatment of pemphigus vulgaris with a combination of rituximab and high-potency topical corticosteroids. JAMA Dermatol 151:200\u2013203. \n                    https:\/\/doi.org\/10.1001\/jamadermatol.2014.2421","journal-title":"JAMA Dermatol"},{"key":"1881_CR9","doi-asserted-by":"publisher","unstructured":"Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, Caillot F, Golinski ML, Labeille B, Picard-Dahan C, Paul C, Richard M-A, Bouaziz JD, Duvert-Lehembre S, Bernard P, Caux F, Alexandre M, Ingen-Housz-Oro S, Vabres P, Delaporte E, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D\u2019Incan M, Bedane C, B\u00e9n\u00e9ton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Vermeulin T, Benichou J, Musette P First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet 389:2031\u20132040. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(17)30070-3","DOI":"10.1016\/S0140-6736(17)30070-3"},{"key":"1881_CR10","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1001\/archdermatol.2012.1522","volume":"148","author":"L Lunardon","year":"2012","unstructured":"Lunardon L, Tsai KJ, Propert KJ, Fett N, Stanley JR, Werth VP, Tsai DE, Payne AS (2012) Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol 148:1031\u20131036. \n                    https:\/\/doi.org\/10.1001\/archdermatol.2012.1522","journal-title":"Arch Dermatol"},{"key":"1881_CR11","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1038\/jid.2008.178","volume":"128","author":"H Mouquet","year":"2008","unstructured":"Mouquet H, Musette P, Gougeon ML, Jacquot S, Lemercier B, Lim A, Gilbert D, Dutot I, Roujeau JC, D\u2019Incan M, Bedane C, Tron F, Joly P (2008) B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol 128:2859\u20132869. \n                    https:\/\/doi.org\/10.1038\/jid.2008.178","journal-title":"J Invest Dermatol"},{"key":"1881_CR12","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","volume":"58","author":"DF Murrell","year":"2008","unstructured":"Murrell DF, Dick S, Ahmed AR, Amagai M, Barnadas MA, Borradori L, Bystryn JC, Cianchini G, Diaz L, Fivenson D, Hall R, Harman KE, Hashimoto T, Hertl M, Hunzelmann N, Iranzo P, Joly P, Jonkman MF, Kitajima Y, Korman NJ, Martin LK, Mimouni D, Pandya AG, Payne AS, Rubenstein D, Shimizu H, Sinha AA, Sirois D, Zillikens D, Werth VP (2008) Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 58:1043\u20131046. \n                    https:\/\/doi.org\/10.1016\/j.jaad.2008.01.012","journal-title":"J Am Acad Dermatol"},{"key":"1881_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-017-8662-z","volume":"54","author":"R Pollmann","year":"2018","unstructured":"Pollmann R, Schmidt T, Eming R, Hertl M (2018) Pemphigus: a comprehensive review on pathogenesis, clinical presentation and novel therapeutic approaches. Clin Rev Allergy Immunol 54:1\u201325. \n                    https:\/\/doi.org\/10.1007\/s12016-017-8662-z","journal-title":"Clin Rev Allergy Immunol"},{"key":"1881_CR14","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1038\/jid.2009.72","volume":"129","author":"M Rosenbach","year":"2009","unstructured":"Rosenbach M, Murrell DF, Bystryn JC, Dulay S, Dick S, Fakharzadeh S, Hall R, Korman NJ, Lin J, Okawa J, Pandya AG, Payne AS, Rose M, Rubenstein D, Woodley D, Vittorio C, Werth BB, Williams EA, Taylor L, Troxel AB, Werth VP (2009) Reliability and convergent validity of two outcome instruments for pemphigus. J Invest Dermatol 129:2404\u20132410. \n                    https:\/\/doi.org\/10.1038\/jid.2009.72","journal-title":"J Invest Dermatol"},{"key":"1881_CR15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.4103\/0378-6323.174379","volume":"82","author":"VK Sharma","year":"2016","unstructured":"Sharma VK, Bhari N, Gupta S, Sahni K, Khanna N, Ramam M, Sethuraman G (2016) Clinical efficacy of rituximab in the treatment of pemphigus: a retrospective study. Indian J Dermatol Venereol Leprol 82:389\u2013394. \n                    https:\/\/doi.org\/10.4103\/0378-6323.174379","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"1881_CR16","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1182\/blood-2007-12-129262","volume":"112","author":"R Stasi","year":"2008","unstructured":"Stasi R, Cooper N, Del Poeta G, Stipa E, Laura Evangelista M, Abruzzese E, Amadori S (2008) Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 112:1147\u20131150. \n                    https:\/\/doi.org\/10.1182\/blood-2007-12-129262","journal-title":"Blood"},{"key":"1881_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.intimp.2017.10.027","volume":"53","author":"S Tavakolpour","year":"2017","unstructured":"Tavakolpour S (2017) Current and future treatment options for pemphigus: is it time to move towards more effective treatments? Int Immunopharmacol 53:133\u2013142. \n                    https:\/\/doi.org\/10.1016\/j.intimp.2017.10.027","journal-title":"Int Immunopharmacol"},{"key":"1881_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.intimp.2017.11.005","volume":"54","author":"S Tavakolpour","year":"2018","unstructured":"Tavakolpour S, Mahmoudi H, Balighi K, Abedini R, Daneshpazhooh M (2018) Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: a systematic review. Int Immunopharmacol 54:131\u2013138. \n                    https:\/\/doi.org\/10.1016\/j.intimp.2017.11.005","journal-title":"Int Immunopharmacol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00403-018-1881-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-018-1881-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-018-1881-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T07:59:02Z","timestamp":1575273542000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00403-018-1881-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["1881"],"URL":"https:\/\/doi.org\/10.1007\/s00403-018-1881-1","relation":{},"ISSN":["0340-3696","1432-069X"],"issn-type":[{"value":"0340-3696","type":"print"},{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,1]]},"assertion":[{"value":"22 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study approved by research ethics committees in the Tehran University of Medical Sciences.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}